Premium
The impact of donor full‐length KIR2DS4 in the development of acute and chronic GVHD after unrelated allogeneic HSCT
Author(s) -
An Kang,
Li Benshang,
Luo Changying,
Wang Jianmin,
Luo Chengjuan,
Chen Jing
Publication year - 2020
Publication title -
pediatric transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.457
H-Index - 69
eISSN - 1399-3046
pISSN - 1397-3142
DOI - 10.1111/petr.13728
Subject(s) - medicine , genotyping , incidence (geometry) , subgroup analysis , hematopoietic stem cell transplantation , cumulative incidence , gastroenterology , immunology , oncology , transplantation , gene , genotype , biology , confidence interval , genetics , physics , optics
Background Killer Ig‐like receptor 2DS4 (KIR2DS4) is the most prevalent activating killer Ig‐like receptor gene. It is divergent and encodes either full‐length or deleted allele variants. The studies of donor killer KIR2DS4 in unrelated allogeneic hematopoietic stem cell transplantations were limited. Methods KIR and HLA genotyping were determined in 75 pairs of Chinese pediatric hematologic malignancy patients. Results Among the 75 donor‐recipient pairs, 77.3% (58/75) of the donors were positive for full‐length KIR2DS4 and 22.7% (17/75) were negative. Patients who had donors positive for full‐length KIR2DS4 had higher cumulative incidence of aGVHD than patients whose donor negative for full‐length KIR2DS4 (86.2% versus 76.5%, P = .038). Multivariate analysis showed full‐length KIR2DS4 was the significant factor for I‐IV aGVHD (HR = 2.166, 95% CI: 1.01‐4.26, P = .025). Subgroup analysis showed that AML and CML patients who received donors negative for full‐length KIR2DS4 have a higher cumulative incidences of cGVHD (75% vs 62%, P = .008). There were no significant effects of full‐length KIR2DS4 on overall survival ( P = .13), relapse‐free survival ( P = .14), CMV reactivation ( P = .52), and relapse (HR = 0.38, 95% CI: 0.09‐1.6, P = .1875). Conclusions Our findings indicated a significant correlation of donor full‐length KIR2DS4 on aGVHD and cGVHD. These results suggested that combining KIR and HLA genotyping may help make a better sense of transplants in these patients.